image
Healthcare - Medical - Devices - NYSE - US
$ 12.58
5.41 %
$ 579 M
Market Cap
-1.53
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one AVNS stock under the worst case scenario is HIDDEN Compared to the current market price of 12.6 USD, Avanos Medical, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one AVNS stock under the base case scenario is HIDDEN Compared to the current market price of 12.6 USD, Avanos Medical, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one AVNS stock under the best case scenario is HIDDEN Compared to the current market price of 12.6 USD, Avanos Medical, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AVNS

image
$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
688 M REVENUE
2.15%
-396 M OPERATING INCOME
-9433.33%
-392 M NET INCOME
-534.47%
101 M OPERATING CASH FLOW
210.80%
-27.5 M INVESTING CASH FLOW
-127.31%
-49.1 M FINANCING CASH FLOW
47.88%
180 M REVENUE
5.40%
-418 M OPERATING INCOME
-3487.50%
800 K NET INCOME
-81.40%
57.9 M OPERATING CASH FLOW
151.74%
-7.6 M INVESTING CASH FLOW
36.67%
-27.4 M FINANCING CASH FLOW
-71.25%
Balance Sheet Avanos Medical, Inc.
image
Current Assets 393 M
Cash & Short-Term Investments 108 M
Receivables 133 M
Other Current Assets 153 M
Non-Current Assets 761 M
Long-Term Investments 0
PP&E 145 M
Other Non-Current Assets 616 M
9.33 %11.51 %13.25 %12.55 %53.37 %Total Assets$1.2b
Current Liabilities 166 M
Accounts Payable 54.3 M
Short-Term Debt 20.3 M
Other Current Liabilities 91.3 M
Non-Current Liabilities 160 M
Long-Term Debt 125 M
Other Non-Current Liabilities 34.5 M
16.67 %6.23 %28.03 %38.47 %10.59 %Total Liabilities$325.7m
EFFICIENCY
Earnings Waterfall Avanos Medical, Inc.
image
Revenue 688 M
Cost Of Revenue 306 M
Gross Profit 381 M
Operating Expenses 778 M
Operating Income -396 M
Other Expenses -4.1 M
Net Income -392 M
800m800m600m600m400m400m200m200m00(200m)(200m)(400m)(400m)688m(306m)381m(777m)(396m)4m(392m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
55.44% GROSS MARGIN
55.44%
-57.60% OPERATING MARGIN
-57.60%
-57.01% NET MARGIN
-57.01%
-47.33% ROE
-47.33%
-33.97% ROA
-33.97%
-37.63% ROIC
-37.63%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Avanos Medical, Inc.
image
200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -392 M
Depreciation & Amortization 45.5 M
Capital Expenditures -17.8 M
Stock-Based Compensation 13.8 M
Change in Working Capital 35 M
Others 394 M
Free Cash Flow 82.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Avanos Medical, Inc.
image
Wall Street analysts predict an average 1-year price target for AVNS of $25.8 , with forecasts ranging from a low of $20 to a high of $33 .
AVNS Lowest Price Target Wall Street Target
20 USD 58.98%
AVNS Average Price Target Wall Street Target
25.8 USD 105.35%
AVNS Highest Price Target Wall Street Target
33 USD 162.32%
Price
Max Price Target
Min Price Target
Average Price Target
353530302525202015151010Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Avanos Medical, Inc.
image
Sold
0-3 MONTHS
107 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
AVNS Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down Strength in Avanos' SNS segment drives its first-quarter 2025 performance despite global macroeconomic challenges. zacks.com - 1 week ago
Avanos Medical, Inc. (AVNS) Q1 2025 Earnings Call Transcript Avanos Medical, Inc. (NYSE:AVNS ) Q1 2025 Earnings Conference Call May 6, 2025 9:00 AM ET Company Participants Scott Galovan - Vice President of Strategy and Corporate Development Dave Pacitti - Chief Executive Officer Jason Pickett - Interim Chief Financial Officer and Treasurer Conference Call Participants Rick Wise - Stifel Daniel Stauder - Citizens JMP Operator Good morning, ladies and gentlemen, and welcome to the Avanos Medical, Avanos First Quarter 2025 Earnings Call. [Operator Instructions] This call is being recorded on Tuesday, May 6, 2025. seekingalpha.com - 1 week ago
Avanos Medical (AVNS) Q1 Earnings and Revenues Top Estimates Avanos Medical (AVNS) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.22 per share a year ago. zacks.com - 1 week ago
Avanos Medical, Inc. Announces First Quarter 2025 Results ALPHARETTA, Ga. , May 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported first quarter 2025 financial results. prnewswire.com - 1 week ago
Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2025 Financial Results ALPHARETTA, Ga. , April 28, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2025 on Tuesday, May 6 at 9 a.m. prnewswire.com - 3 weeks ago
AVNS Stock Gains Following Direct Sales Deal for MIC-KEY in the UK Avanos takes direct control of MIC-KEY sales in the UK, enhancing market presence, customer engagement and service efficiency, starting July 2025. zacks.com - 1 month ago
Avanos Expands Direct Operations for MIC-KEY* Enteral Feeding Products in the UK starting July 2025 ZAVENTEM, Belgium , April 2, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) a global medical technology company, today announced that it will take direct responsibility for the sales and distribution of its MIC-KEY enteral feeding products in the United Kingdom, effective 25 July 2025. This strategic move reflects Avanos' commitment to prioritizing customer needs, enhancing product availability into the future, and providing a seamless experience for healthcare providers and patients. prnewswire.com - 1 month ago
New Strong Sell Stocks for March 24th AVNS, AIRS and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on March 24, 2025. zacks.com - 1 month ago
New Strong Sell Stocks for March 18th AVNS, CARS and CABO have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2025. zacks.com - 2 months ago
Avanos Medical Announces Appointment of David Pacitti as Chief Executive Officer ALPHARETTA, Ga. , March 17, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. prnewswire.com - 2 months ago
New Strong Sell Stocks for March 3rd AVNS, CSX and STZ have been added to the Zacks Rank #5 (Strong Sell) List on March 3, 2025. zacks.com - 2 months ago
AVNS Stock Gains Post Q4 Earnings & Revenue Beat, Margins Contract Strength in Avanos' Digestive Health segment drives its fourth-quarter 2024 performance despite global macroeconomic challenges. zacks.com - 2 months ago
8. Profile Summary

Avanos Medical, Inc. AVNS

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 579 M
Dividend Yield 0.00%
Description Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Contact 5405 Windward Parkway, Alpharetta, GA, 30004 https://avanos.com
IPO Date Oct. 21, 2014
Employees 2227
Officers Mr. Sigfrido Delgado Senior Vice President of Operations Ms. Mojirade James Senior Vice President, General Counsel & Corporate Secretary